Maintenance therapy for recurrent ovarian cancer after second-line treatment
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new investigational drug, raludotatug deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as maintenance treatment after second-line platinum-based chemotherapy for recurrent ovarian cancer. The goal is to keep the cancer from growing longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult assigned female at birth.
- You have high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer.
- You have a documented BRCA or HRD test result.
- You have received two prior lines of platinum-based chemotherapy, and your disease responded or remained stable after the most recent one.
- You are not planning to have a PARP inhibitor as your next maintenance treatment.
- You are physically active (able to do light work) and have acceptable organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
Hear when a new Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.